An interventional study of Electronic health record-based notification of Nanox.AI Coronary Artery Calcification Assessment in Coronary Artery Disease, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Coronary Artery Disease by Brigham and Women's Hospital — 2 open to participants now, 3 under way, none of them phase 3. Coronary Artery Disease · Brigham and Women's Hospital.
Among the 18 studies in Coronary Artery Disease by Brigham and Women's Hospital, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 6 with no phase, and was the 17th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →2 of the 18 studies in Coronary Artery Disease by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 163 across the 12 interventional studies, 2,347 across the 5 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
2 of the studies in Coronary Artery Disease by Brigham and Women's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06235112Brigham and Women's HospitalAI Detection of Incidental Coronary Artery Calcium to Enhance Cardiovascular Disease Prevention | 2027-06-01 |
| NCT01114269Brigham and Women's HospitalPRE-DETERMINE Cohort Study | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Coronary Artery Disease by Brigham and Women's Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
AI INFORM is a multicenter randomized trial that will test the hypothesis that providing clinicians information on the presence and amount of coronary artery calcifications (CAC), will result in initiation or intensification of preventive therapies. The study will use a cloud-based artificial intelligence (AI) platform (Nanox.AI) that can analyze non contrast chest CT and estimate the amount of CAC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Notification to providers of the presence of coronary artery calcification automatically detected by AI based device (software) on chest CT. Recommendation of preventive therapy.
Device: Electronic health record-based notification of Nanox.AI Coronary Artery Calcification Assessment
No notification to providers of the presence of coronary artery calcification on chest CT automatically detected by AI based device (software) on chest CT. No recommendation of preventive therapy.
The intervention involves electronic health record, email, or letter notification about the presence of coronary artery calcification on chest CT and recommendation of preventive therapy. This is based on results of the automatic detection of coronary artery calcification from AI device (software).
Proportion of participants with initiation or intensification of lipid-lowering therapy after intervention
Initiation or intensification of therapy (yes/no) by 6 months after the intervention. Initiation: starting lipid-lowering therapy; intensification: increasing the dose of lipid-lowering therapy
Time frame: 6 months
Average change in LDL-C after intervention
Average quantitative change in LDL-C (low-density lipoprotein cholesterol) between baseline and 12 months after intervention
Time frame: 12 months
Proportion of participants with downstream invasive or noninvasive testing after intervention
Composite outcome: Downstream testing (yes/no) including coronary artery calcium score, coronary CT angiography, invasive coronary angiography, or stress testing by 12 months after the intervention.
Time frame: 12 months
Proportion of participants with major adverse cardiovascular events after intervention
Composite outcome: Occurrence of an adverse cardiovascular event (yes/no) including cardiovascular death, myocardial infarction, or stroke by 12 months after the intervention
Time frame: 12 months
Proportion of participants with initiation or intensification of other preventive therapies after intervention
Initiation or intensification of preventive therapy (yes/no) by 6 months after the intervention. Preventive therapy includes any of the following: aspirin, antihypertensive therapy, metabolic therapy. Initiation: starting preventive therapy; intensification: increasing the dose of preventive therapy
Time frame: 6 months
Plan to share: No — No IPD will be shared
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Jun 2027, 34 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 34 months is close to that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brigham and Women's Hospital →